DxS hires COO in continuing expansion plans
This article was originally published in Clinica
Jeff Devlin has been appointed COO of cancer diagnostics firm DxS (Manchester, UK). Mr Devlin joins from Shire Pharmaceuticals, where he was executive vice-president and an executive committee member. The company said it welcomed the addition of the marketing and physics graduate’s operations and strategy expertise, as the firm continued to expand.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.